Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.
about
Critical appraisal of eculizumab for atypical hemolytic uremic syndromeCurrent treatment of atypical hemolytic uremic syndromeThe importance of C4d in biopsies of kidney transplant recipientsEculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.The use of eculizumab in renal transplantation.Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literatureAntibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options.Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Advances in pharmacotherapy to treat kidney transplant rejection.Complement inhibition as potential new therapy for antibody-mediated rejection.Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Factors influencing treatment of atypical hemolytic uremic syndrome.Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody.Pharmacologic Complement Inhibition in Clinical Transplantation.The role of von Willebrand factor in thrombotic microangiopathy.Applying Genomics in Heart Transplantation.C3 Glomerulopathy.Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
P2860
Q26750692-1C47DF5F-0DDA-4526-952E-2773DC01506BQ27003211-9AA7D6B3-977F-4510-A3CD-9B555844BF77Q27021227-02ED886E-E086-4F4C-85E2-A5611E30650BQ33403196-D51367D3-BDEE-4DA4-8F3E-3D48BF3F3545Q33406570-311AB6AC-BF4E-4832-938F-25CD9C3FFB23Q33409586-9F6D6109-C3C5-468B-92C0-D973AD94D9EEQ33412869-5861AC60-BBD0-46C6-B471-911723B835E5Q33415192-EE1805A9-2B49-478C-8CE5-B103599FE3D5Q33419720-E47C233F-C376-41DF-9F6F-EEA4921EBF28Q33419812-E891BA45-91E9-4588-A7D2-D7A2DCF9BC1CQ38206175-1930E3A6-7BA9-46BB-B65A-2DD6964C28A1Q38392458-16268824-D58F-423F-B871-F1C4DD224517Q38544529-59202BD5-24B3-4AEB-AEF7-933B70532066Q38609238-1132AEFB-6E65-4095-A055-10A8C713C683Q38914719-C36EC841-03B2-44E8-B019-8DA48DA62346Q39309248-26769DA5-F33D-4A67-AAD7-684D1D357C40Q42086661-3F36B387-2484-44EC-8E76-804FA58FB0A2Q42858176-770D0AB5-6762-444E-B00B-1787E78EC354Q45736192-DA1F2470-2E15-4BF1-87B2-2D9C59B588F4Q47104714-6E496E84-151F-4520-A687-88D4D9CE73D3Q48338971-5812348B-F2C3-402B-9949-21331BD16F06Q49834046-7766B47B-B85D-46AF-A9DE-FC1BFA3C33B1Q52876323-EB622BA5-5DF5-4BA2-A53F-1359779D0D80Q53819914-D8C9038C-F5A1-4670-94CA-38E3CD66FF66
P2860
Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Antibody mediated rejection as ...... fully treated with eculizumab.
@en
Antibody mediated rejection as ...... fully treated with eculizumab.
@nl
type
label
Antibody mediated rejection as ...... fully treated with eculizumab.
@en
Antibody mediated rejection as ...... fully treated with eculizumab.
@nl
prefLabel
Antibody mediated rejection as ...... fully treated with eculizumab.
@en
Antibody mediated rejection as ...... fully treated with eculizumab.
@nl
P2093
P2860
P1476
Antibody mediated rejection as ...... fully treated with eculizumab.
@en
P2093
A M Herzenberg
F G Pluthero
J Al-Matrafi
P F Zipfel
P S Thorner
W H A Kahr
P2860
P304
P356
10.1111/J.1600-6143.2012.04124.X
P407
P577
2012-06-08T00:00:00Z